Company news
Atrium Therapeutics, Inc. (NASDAQ:RNA) news
Atrium Therapeutics, Inc. news releases on 6ix. Latest, Jun 17, 2024: Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock…
Press releases — page 2
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
June 16, 2024
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
June 12, 2024
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
June 11, 2024
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
June 11, 2024
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
May 28, 2024
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
May 14, 2024
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 8, 2024
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
May 7, 2024
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
March 3, 2024
Avidity Biosciences Honors Rare Disease Day®
February 28, 2024
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
February 28, 2024
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
February 27, 2024
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
February 19, 2024
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 14, 2024
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
January 4, 2024
Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy
December 12, 2023
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
November 27, 2023
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
November 7, 2023
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
October 6, 2023
Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society
September 25, 2023
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
September 6, 2023
Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference
August 30, 2023
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
August 14, 2023
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
August 7, 2023
Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day
June 19, 2023
Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress
June 7, 2023
Avidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1
May 16, 2023
Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 8, 2023
Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1
April 26, 2023
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
April 23, 2023
Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting
April 16, 2023
Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA™ Trial on April 27, 2023
April 12, 2023
Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting
March 29, 2023
Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference
March 12, 2023
Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
February 27, 2023
Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
February 26, 2023
Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader
February 22, 2023
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
February 13, 2023
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
January 17, 2023
Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock
December 14, 2022
Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics
December 13, 2022
Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
November 7, 2022
Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
October 10, 2022
Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society
October 5, 2022
Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy
September 28, 2022
Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial
September 26, 2022
Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs
September 6, 2022
Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
August 8, 2022
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
August 1, 2022
Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program
June 16, 2022